Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q1 FY2012 Earnings Presentation
9 slides from Alembic Pharmaceuticals's earnings presentation, June 2011
Slide 1: Investors Update – Q1FY12
Alembic Pharmaceuticals Limited Investors Update – Q1FY12 • Net sales up 34% at Rs 345 crores for the quarter against Rs. 257 crores. • Domestic formulations sales up 19% for the quarter at Rs. 172 crores against Rs. 145 crores in corresponding period previous year • International generics up 127% a
Slide 2: Management Discussion – Q1FY12
Management Discussion – Q1FY12 Alembic Pharamaceuticals Limited reported sales for the quarter ended June 30 2011 at Rs 344.72 crores up by 34% compared to Rs 256.62 crores in corresponding quarter previous year, while profit before tax for the quarter ended June 30, 2011 is Rs. 35.47 crores against
Slide 3: Domestic brands and therapy growth above market
Gastro, Cardio, Anti Diabetic, Gynaec and Opthal are growing at higher than respective market growth. Alembic has four brands in the list of top 300 brands of the industry i.e. ‘Azithral’ , ‘Roxid’, ‘Althrocin’, and ‘Wikoryl’. The company continues to make investment in the domestic branded business
Slide 4: International Generics
¾ International Generics International generics sales to the regulated markets grew by 127% to Rs. 61.15 crores from Rs. 26.97 Crores over corresponding quarter last year Branded formulations sales to semi regulated markets grew by 71% to Rs. 11.32 crores from Rs. 6.61 crores. Cumulative ANDA filing
Slide 5: API Business
¾ API Business Total API sales up 26% at Rs. 95.48 crores against Rs. 75.96 crores in PY. Domestic API increased 162% to Rs. 34.75 crores against Rs. 13.27 crores Export API recorded sales of Rs. 60.73 crores against Rs. 62.69 crores in corresponding quarter last year. One DMF filed during the quart
Slide 6: Financial and Operating Result – Q1FY12
Financial and Operating Result – Q1FY12 Financial and Operating Result – Q1FY12 Particulars Rs. lacs Income from Operations 34512 Total Expenditure 29477 - (Increase) / decrease in stock (1174) - Consumption of Raw Material 11802 - Consumption of Traded Goods 6546 - Employee cost 3944 - Research and
Slide 7: Summary of total revenue (consolidated) for the quarter
Summary of total revenue (consolidated) for the quarter is as under: (Rs. in Lacs) Particulars Q1 FY12 Q1 FY11 % Change Formulation Domestic 17244 14496 19% International Branded 1132 661 71% International Generics 6115 2697 127% API Domestic 3475 1327 162% International 6073 6269 (-)3% Export incen
Slide 8: Scheme of Rearrangement
Scheme of Rearrangement: The Hon’ble High Court of Gujarat, vide order dated 24/01/2011, has approved the Scheme of Arrangement in the nature of demerger of the “Pharmaceutical Undertaking” of Alembic Limited and transfer of the same to Alembic Pharmaceuticals Limited (earlier known as “Alembic Phar
Slide 9: About Alembic Pharmaceuticals Limited
About Alembic Pharmaceuticals Limited Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market lea
Alembic Pharmaceuticals — Q1 FY2012 Earnings Presentation on 6ix